Pressemeddelelse

Active Biotech’s patent for laquinimod in eye disorders will be granted in the US

Lund, November 13, 2024, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a Notice of Allowance for Active Biotech’s patent application related to methods of treating eye diseases associated with excessive vascularization using laquinimod. The patent, which was filed under application no. 17/939,109, will provide protection and market exclusivity in this field of use until 2040.

“This US patent is a result of our continued work with our laquinimod patent portfolio to optimize protection for its use in eye diseases with high medical need,” said Active Biotech’s CEO Helén Tuvesson.

The patent covers the medical use of laquinimod for treatment of sight-threatening eye disorders, e.g. wet age-related macular degeneration (wet AMD), corneal neovascularization, choroidal neovascularization, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy. In the EU, Active Biotech has already been granted patent rights covering laquinimod’s use in treatment of eye diseases associated with excessive vascularization.

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies has been initiated. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

About laquinimod

Laquinimod is a first-in-class immunomodulator that promotes immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment. Laquinimod is developed as a new treatment for inflammatory eye disorders in the first step non-infectious uveitis. Laquinimod was previously studied in patients with neurodegenerative and inflammatory diseases, including a phase III randomized study program in multiple sclerosis (MS) patients. The clinical safety and tolerability of laquinimod is well known and preclinical data in disease models support the use of laquinimod for the treatment of severe eye disorders including uveitis and eye disorders with abnormal vascularization.
For more information about the study please see clinicaltrials.gov NCT06161415.